RetinaCME
LECTURECME

Retina 2019: What's New in Tie2?

Author(s)/Faculty: Dilsher S. Dhoot, MD; Carl D. Regillo, MD, FACS
Release Date: 2/21/2019Expiration Date: 2/20/2020
Credit Type: CMENumber of Credits: 0.75
Content Type: LectureProvider:
The integration of intravitreal anti-vascular endothelial growth factor (VEGF) therapy into management algorithms for the treatment of patients with neovascular retinal disease has revolutionized outcomes in these patients. However, clinical studies have demonstrated that approximately two-thirds of treated patients have a suboptimal or no response to anti-VEGF treatment regimens, demonstrating a need for the identification of new molecular targets for therapeutic intervention. Currently, molecular pathways that are involved in abnormal angiogenesis and increased vascular permeability are being targeted in clinical studies. One such pathway is the Tie2 angiogenic pathway, and promising novel agents that target it are currently being assessed for the treatment of neovascular disease. In this educational activity, experts in the field review real-world evidence for the long-term effectiveness of current therapies for neovascular retinal disease and evaluate emerging modalities targeting the angiopoietin/Tie2 pathway to treat neovascular retinal disease.